Allo-SCT using BU, CY and melphalan for children with AML in second CR

R Beier; M H Albert; P Bader; A Borkhardt; U Creutzig; M Eyrich; K Ehlert; B Gruhn; J Greil; R Handgretinger; W Holter; T Klingebiel; B Kremens; P Lang; C Mauz-Körholz; R Meisel; I Müller; C Peters; D Reinhardt; P Sedlacek; A Schulz; F R Schuster; A Schrauder; B Strahm; K W Sykora; W Wössmann; M Zimmermann; M G Sauer

doi:10.1038/bmt.2012.204

Allo-SCT using BU, CY and melphalan for children with AML in second CR

Standard

Allo-SCT using BU, CY and melphalan for children with AML in second CR. / Beier, R; Albert, M H; Bader, P; Borkhardt, A; Creutzig, U; Eyrich, M; Ehlert, K; Gruhn, B; Greil, J; Handgretinger, R; Holter, W; Klingebiel, T; Kremens, B; Lang, P; Mauz-Körholz, C; Meisel, R; Müller, I; Peters, C; Reinhardt, D; Sedlacek, P; Schulz, A; Schuster, F R; Schrauder, A; Strahm, B; Sykora, K W; Wössmann, W; Zimmermann, M; Sauer, M G.

In: BONE MARROW TRANSPL, Vol. 48, No. 5, 01.05.2013, p. 651-6.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Transfer › peer-review

Harvard

Beier, R, Albert, MH, Bader, P, Borkhardt, A, Creutzig, U, Eyrich, M, Ehlert, K, Gruhn, B, Greil, J, Handgretinger, R, Holter, W, Klingebiel, T, Kremens, B, Lang, P, Mauz-Körholz, C, Meisel, R, Müller, I, Peters, C, Reinhardt, D, Sedlacek, P, Schulz, A, Schuster, FR, Schrauder, A, Strahm, B, Sykora, KW, Wössmann, W, Zimmermann, M & Sauer, MG 2013, 'Allo-SCT using BU, CY and melphalan for children with AML in second CR', BONE MARROW TRANSPL, vol. 48, no. 5, pp. 651-6. https://doi.org/10.1038/bmt.2012.204

APA

Beier, R., Albert, M. H., Bader, P., Borkhardt, A., Creutzig, U., Eyrich, M., Ehlert, K., Gruhn, B., Greil, J., Handgretinger, R., Holter, W., Klingebiel, T., Kremens, B., Lang, P., Mauz-Körholz, C., Meisel, R., Müller, I., Peters, C., Reinhardt, D., ... Sauer, M. G. (2013). Allo-SCT using BU, CY and melphalan for children with AML in second CR. BONE MARROW TRANSPL, 48(5), 651-6. https://doi.org/10.1038/bmt.2012.204

Vancouver

Beier R, Albert MH, Bader P, Borkhardt A, Creutzig U, Eyrich M et al. Allo-SCT using BU, CY and melphalan for children with AML in second CR. BONE MARROW TRANSPL. 2013 May 1;48(5):651-6. https://doi.org/10.1038/bmt.2012.204

Bibtex

@article{2c5815acb4a2431b8377c4dc46a9d35f,

title = "Allo-SCT using BU, CY and melphalan for children with AML in second CR",

abstract = "Based on the results from the AML-BFM 98 trial, hematopoietic SCT (HSCT) is recommended for children with AML in second CR only. Here, we retrospectively analyze interphase data of children who underwent HSCT after myeloablative conditioning with BU, CY, and melphalan (BuCyMel) for AML in second remission (CR2) between 1998 and 2009. Out of 152 children, transplant data were available on 109 individuals. Sixty out of 109 children (55%) received BuCyMel. Median age at HSCT was 12.2 years (range 3.0; 18.3). GVHD prophylaxis mostly consisted of CsA and short term MTX with or without antithymocyte globulin. Matched-sibling donors were used for 6/60 analyzed recipients, the remainder either received grafts from matched unrelated (30/60) or mismatched donors. OS after 5 years was 62% (s.e. 6%), relapse incidence 35% (18/60 children) and treatment-related mortality accounted for 12% (7/60) of fatal events. In conclusion, even taking into account possible selection bias in this retrospective analysis, HSCT in CR2 using BuCyMel resulted in a respectable OS. Based on this data the prospective, controlled and centrally monitored AML SCT-BFM 2007 trial has started to recruit patients in January 2010 aiming to generate valid outcome data for further strategy decisions.",

keywords = "Adolescent, Antineoplastic Combined Chemotherapy Protocols, Busulfan, Child, Child, Preschool, Cohort Studies, Combined Modality Therapy, Cyclophosphamide, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Male, Melphalan, Randomized Controlled Trials as Topic, Retrospective Studies, Transplantation Conditioning",

author = "R Beier and Albert, {M H} and P Bader and A Borkhardt and U Creutzig and M Eyrich and K Ehlert and B Gruhn and J Greil and R Handgretinger and W Holter and T Klingebiel and B Kremens and P Lang and C Mauz-K{\"o}rholz and R Meisel and I M{\"u}ller and C Peters and D Reinhardt and P Sedlacek and A Schulz and Schuster, {F R} and A Schrauder and B Strahm and Sykora, {K W} and W W{\"o}ssmann and M Zimmermann and Sauer, {M G}",

year = "2013",

month = may,

day = "1",

doi = "10.1038/bmt.2012.204",

language = "English",

volume = "48",

pages = "651--6",

journal = "BONE MARROW TRANSPL",

issn = "0268-3369",

publisher = "NATURE PUBLISHING GROUP",

number = "5",

}

RIS

TY - JOUR

T1 - Allo-SCT using BU, CY and melphalan for children with AML in second CR

AU - Beier, R

AU - Albert, M H

AU - Bader, P

AU - Borkhardt, A

AU - Creutzig, U

AU - Eyrich, M

AU - Ehlert, K

AU - Gruhn, B

AU - Greil, J

AU - Handgretinger, R

AU - Holter, W

AU - Klingebiel, T

AU - Kremens, B

AU - Lang, P

AU - Mauz-Körholz, C

AU - Meisel, R

AU - Müller, I

AU - Peters, C

AU - Reinhardt, D

AU - Sedlacek, P

AU - Schulz, A

AU - Schuster, F R

AU - Schrauder, A

AU - Strahm, B

AU - Sykora, K W

AU - Wössmann, W

AU - Zimmermann, M

AU - Sauer, M G

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Based on the results from the AML-BFM 98 trial, hematopoietic SCT (HSCT) is recommended for children with AML in second CR only. Here, we retrospectively analyze interphase data of children who underwent HSCT after myeloablative conditioning with BU, CY, and melphalan (BuCyMel) for AML in second remission (CR2) between 1998 and 2009. Out of 152 children, transplant data were available on 109 individuals. Sixty out of 109 children (55%) received BuCyMel. Median age at HSCT was 12.2 years (range 3.0; 18.3). GVHD prophylaxis mostly consisted of CsA and short term MTX with or without antithymocyte globulin. Matched-sibling donors were used for 6/60 analyzed recipients, the remainder either received grafts from matched unrelated (30/60) or mismatched donors. OS after 5 years was 62% (s.e. 6%), relapse incidence 35% (18/60 children) and treatment-related mortality accounted for 12% (7/60) of fatal events. In conclusion, even taking into account possible selection bias in this retrospective analysis, HSCT in CR2 using BuCyMel resulted in a respectable OS. Based on this data the prospective, controlled and centrally monitored AML SCT-BFM 2007 trial has started to recruit patients in January 2010 aiming to generate valid outcome data for further strategy decisions.

AB - Based on the results from the AML-BFM 98 trial, hematopoietic SCT (HSCT) is recommended for children with AML in second CR only. Here, we retrospectively analyze interphase data of children who underwent HSCT after myeloablative conditioning with BU, CY, and melphalan (BuCyMel) for AML in second remission (CR2) between 1998 and 2009. Out of 152 children, transplant data were available on 109 individuals. Sixty out of 109 children (55%) received BuCyMel. Median age at HSCT was 12.2 years (range 3.0; 18.3). GVHD prophylaxis mostly consisted of CsA and short term MTX with or without antithymocyte globulin. Matched-sibling donors were used for 6/60 analyzed recipients, the remainder either received grafts from matched unrelated (30/60) or mismatched donors. OS after 5 years was 62% (s.e. 6%), relapse incidence 35% (18/60 children) and treatment-related mortality accounted for 12% (7/60) of fatal events. In conclusion, even taking into account possible selection bias in this retrospective analysis, HSCT in CR2 using BuCyMel resulted in a respectable OS. Based on this data the prospective, controlled and centrally monitored AML SCT-BFM 2007 trial has started to recruit patients in January 2010 aiming to generate valid outcome data for further strategy decisions.

KW - Adolescent

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Busulfan

KW - Child

KW - Child, Preschool

KW - Cohort Studies

KW - Combined Modality Therapy

KW - Cyclophosphamide

KW - Female

KW - Graft vs Host Disease

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Leukemia, Myeloid, Acute

KW - Male

KW - Melphalan

KW - Randomized Controlled Trials as Topic

KW - Retrospective Studies

KW - Transplantation Conditioning

U2 - 10.1038/bmt.2012.204

DO - 10.1038/bmt.2012.204

M3 - SCORING: Journal article

C2 - 23103678

VL - 48

SP - 651

EP - 656

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 5

ER -